SINOPHARM (01099) announced its annual results for the year ended December 31, 2025. The Group recorded revenue of RMB 575.168 billion, representing a decrease of 1.6% year-on-year. Profit attributable to owners of the parent company was RMB 7.155 billion, an increase of 1.5% compared to the previous year. Earnings per share were RMB 2.29, and the Board recommended a final dividend of RMB 0.69 per share.

In terms of operational efficiency improvements, the Group adhered to its strategy focused on economies of scale and cost leadership, advancing expense reduction and lean management. By the end of 2025, the Group's overall expense ratio decreased by 0.25 percentage points year-on-year, effectively offsetting the impact of the decline in gross profit. During the reporting period, net cash inflow from operating activities was RMB 14.138 billion, an increase of RMB 2.592 billion compared to the same period last year, highlighting effective cash flow management. The growth in accounts receivable narrowed significantly, indicating the success of targeted management efforts in this area. The asset-liability ratio decreased by 2.12 percentage points year-on-year.

Leveraging improved internal governance efficiency, the Group effectively withstood market volatility pressures. The operating profit margin increased by 0.02 percentage points year-on-year, demonstrating the business's robust risk resilience and developmental stamina. This performance laid a solid foundation for the successful conclusion of the "14th Five-Year Plan" period and the strategic planning for the "15th Five-Year Plan."

In 2025, the Group concentrated on its primary task of high-quality development. It scientifically assessed market conditions and competitive landscapes across regions, actively expanded market share, and drove quality and efficiency improvements through reform and innovation. During the reporting period, the three main business segments continued their differentiated development trajectories. Revenue from the pharmaceutical distribution segment accounted for 72.79% of the total, down 0.37 percentage points year-on-year. The medical device distribution segment contributed 19.32% of revenue, slightly down by 0.09 percentage points. The pharmaceutical retail segment's revenue share reached 6.42%, an increase of 0.50 percentage points compared to the previous year.